Story · Medicine & Biotech
STAT+: Zolgensma tumor cases show risks of a common gene therapy tool
7 outlets · first reported by STAT Biotech on · latest · 92 hours of coverage · 3 countries
For two decades, researchers debated whether adeno-associated viruses (AAVs), the small viruses used to deliver new genes into thousands of patients, could in certain cases drive tumors. That debate is over. A series of cases this year has presented powerful evidence that AAVs can cause cancer… (STAT News)
Coverage, in order
-
STAT+: Novartis cites cases of previously unknown tumors possibly tied to its SMA gene therapyNovartis has acknowledged seven previously unknown instances in which tumors were found in children who were treated with its spinal muscular atrophy therapy, a surprising development that has raised concerns among families, physicians, and patient advocacy groups. The cases, which for the moment…
-
STAT+: Zolgensma tumor cases show risks of a common gene therapy toolFor two decades, researchers debated whether adeno-associated viruses (AAVs), the small viruses used to deliver new genes into thousands of patients, could in certain cases drive tumors. That debate is over. A series of cases this year has presented powerful evidence that AAVs can cause cancer…
-
Novartis reveals cancer cases possibly linked to gene therapy ZolgensmaThe occurrence of cancer in nine recipients — two of which involved evidence that a viral delivery tool integrated into patient DNA — could raise new questions for the gene therapy field.
-
Novartis Confirms Nine Cases of Tumors in Children Treated with Gene Therapy Zolgensma
Novartis has confirmed nine reports—seven of them newly disclosed—in which tumors have developed in children treated with its marketed spinal muscular atrophy gene therapy Zolgensma ® (onasemnogene abeparvovec-xioi). “Of those, two cases to date have shown evidence of vector integration into the…
-
Gene Therapy Under Scrutiny After Nine Tumor Reports(MedPage Today) -- Drugmaker Novartis acknowledged Thursday that there have been nine reports of tumors in children treated with its gene therapy onasemnogene abeparvovec (Zolgensma) for spinal muscular atrophy (SMA). Two of the tumor cases were...
-
STAT+: Gene therapy’s long-debated cancer risk materializesWant to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. The tumors possibly connected to pediatric gene therapies make me sad. Babies. The need-to-know this morning Vir Biotechnology said monthly injections of two experimental…
Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.